{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:51:34Z","timestamp":1777866694743,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>To 18 premature apneic patients refractory to theophylline, doxapram (0.5-2.5\nmg\/kg\/h) was administered in combination with therapeutic doses of theophylline. Doxapram\nconcentrations in serum were measured 48 h after commencement of the infusion and\nthen in 2-hour intervals during a 6-8 h withdrawal. Total body clearance (dose\/C(SS)) of the\ndrug ranged from 0.20 to 0.56 liter\/h in 13 patients and 1.14 to 1.75 liter\/h in 4 patients\nsuggesting a binomial distribution in the disposition kinetics of the drug. Other pharmacokinetic\nindices, although variable, did not exhibit binomial distribution. The mean volume\nof distribution and half-life of doxapram were 7.33 \u00b1 4.55 liter\/kg and 8.17 \u00b1 4.13h,\nrespectively. Based on our calculations to accelerate the attainment of a steady-state plasma\nconcentration (C(SS)) of approximately 1.5 mg\/l, a loading dose of 5.5 mg\/kg and a maintenance\ndose of 1 mg\/kg\/h along with serum concentration monitoring are recommended.<\/jats:p>","DOI":"10.1159\/000457699","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:09:02Z","timestamp":1502471342000},"page":"253-257","source":"Crossref","is-referenced-by-count":14,"title":["Doxapram Dosage Regimen in Apnea of Prematurity Based on\nPharmacokinetic Data"],"prefix":"10.1159","author":[{"given":"Fakhreddin","family":"Jamali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith J.","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil N.","family":"Finer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald T.","family":"Coutts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Torok-Both","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:09:12Z","timestamp":1777540152000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457699","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}